The curative action of ATRA (at a therapeutic concentration of 10−6 M) in PML-RARα associated APL, as part of a precision medicine combination therapy in conjunction with arsenic trioxide (As2O3), is predicated on the ability of the compounds to bind directly the RARα and PML moieties of the fusion protein, respectively, to promote its proteasomal degradation and activation of differentiation pathway genes (de The et al., 2017). The gene discussed is RARA; the disease is acute promyelocytic leukemia.